Vascular and Nonvascular Roles of VEGF in Bone Development

  • Christa Maes
  • Geert Carmeliet
Part of the Molecular Biology Intelligence Unit book series (MBIU)


The majority of bones in the skeleton develop through the process of endochondral ossification. During this process, avascular cartilage becomes gradually replaced by highly vascularized bone tissue. VEGF is an essential mediator of all 3 key vascularization stages of endochondral bone development, and, in addition, exerts multiple nonvascular functions during each of these stages by acting directly upon the involved bone cells. In this chapter, we will discuss the various lines of evidence which demonstrate that the three major VEGF isoforms are essential to coordinate bone vascularization, cartilage morphogenesis and ossification during endochondral bone formation.


Vascular Endothelial Growth Factor Growth Plate Bone Development Ossification Center Endochondral Ossification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gerber HP, Vu TH, Ryan AM et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5:623–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Haigh JJ, Gerber HP, Ferrara N et al. Conditional inactivation of VEGF-A in areas of collagen2al expression results in embryonic lethality in the heterozygous state. Development 2000; 127:1445–1453.PubMedGoogle Scholar
  3. 3.
    Zelzer E, Mamluk R, Ferrara N et al. VEGFA is necessary for chondrocyte survival during bone development. Development 2004; 131:2161–2171.PubMedCrossRefGoogle Scholar
  4. 4.
    Maes C, Carmeliet P, Moermans K et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 2002; 111:61–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Maes C, Stockmans I, Moermans K et al. Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest 2004; 113:188–199.PubMedGoogle Scholar
  6. 6.
    Zelzer E, McLean W, Ng YS et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129:1893–1904.PubMedGoogle Scholar
  7. 7.
    Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332–336.PubMedCrossRefGoogle Scholar
  8. 8.
    Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002; 2:389–406.PubMedCrossRefGoogle Scholar
  9. 9.
    Zelzer E, Glotzer DJ, Hartmann C et al. Tissue specific regulation of VEGF expression during bone development requires Cbfal/Runx2. Mech Dev 2001; 106:97–106.PubMedCrossRefGoogle Scholar
  10. 10.
    Schipani E, Ryan HE, Didrickson S et al. Hypoxia in cartilage: HIF-1 alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001; 15:2865–2876.PubMedGoogle Scholar
  11. 11.
    Grimshaw MJ, Mason RM. Bovine articular chondrocyte function in vitro depends upon oxygen tension. Osteoarthritis Cartilage 2000; 8:386–392.PubMedCrossRefGoogle Scholar
  12. 12.
    Cramer T, Schipani E, Johnson RS et al. Expression of VEGF isoforms by epiphyseal chondrocytes during low-oxygen tension is HIF-1 alpha dependent. Osteoarthritis Cartilage 2004; 12:433–439.PubMedCrossRefGoogle Scholar
  13. 13.
    Pufe T, Mentlein R, Tsokos M et al. VEGF expression in adult permanent thyroid cartilage: Implications for lack of cartilage ossification. Bone 2004; 35:543–552.PubMedCrossRefGoogle Scholar
  14. 14.
    Carlevaro MF, Cermelli S, Cancedda R et al. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: Auto-paracrine role during endochondral bone formation. J Cell Sci 2000; 113:59–69.PubMedGoogle Scholar
  15. 15.
    Deckers MML, Karperien M, van der Bent C et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000; 141:1667–1674.PubMedCrossRefGoogle Scholar
  16. 16.
    Harper J, Gerstenfeld LC, Klagsbrun M. Neuropilin-1 expression in osteogenic cells: Down-regulation during differentiation of osteoblasts into osteocytes. J Cell Biochem 2001; 81:82–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Akeno N, Czyzyk-Krzeska MF, Gross TS et al. Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia inducible factor-2alpha. Endocrinology 2001; 142:959–962.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim HH, Lee SE, Chung WJ et al. Stabilization of hypoxia-inducible factor-1alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine 2002; 17:14–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Steinbrech DS, Mehrara BJ, Saadeh PB et al. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. Am J Physiol Cell Physiol 2000; 278:C853–C860.PubMedGoogle Scholar
  20. 20.
    Ortega N, Behonick D, Stickens D et al. How proteases regulate bone morphogenesis. Ann NY Acad Sci 2003; 995:109–116.PubMedCrossRefGoogle Scholar
  21. 21.
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337–342.PubMedCrossRefGoogle Scholar
  22. 22.
    Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor VEGFR1. Blood 1996; 87:3336–3343.PubMedGoogle Scholar
  23. 23.
    Niida S, Kaku M, Amano H et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999; 190:293–298.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473:161–164.PubMedCrossRefGoogle Scholar
  25. 25.
    Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: Possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004; 316:573–579.PubMedCrossRefGoogle Scholar
  26. 26.
    Colnot C, Lu C, Hu D et al. Distinguishing the contributions of the perichondrium, cartilage, and vascular endothelium to skeletal development. Dev Biol 2004; 269:55–69.PubMedCrossRefGoogle Scholar
  27. 27.
    Colnot CI, Helms JA. A molecular analysis of matrix remodeling and angiogenesis during long bone development. Mech Dev 2001; 100:245–250.PubMedCrossRefGoogle Scholar
  28. 28.
    Blavier L, Delaissé JM. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995; 108:3649–3659.PubMedGoogle Scholar
  29. 29.
    Engsig MT, Chen QJ, Vu TH et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000; 151:879–889.PubMedCrossRefGoogle Scholar
  30. 30.
    Henriksen K, Karsdal M, Delaisse JM et al. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERKl/2-dependent mechanism. J Biol Chem 2003; 278:48745–48753.PubMedCrossRefGoogle Scholar
  31. 31.
    Mayr-Wohlfart U, Waltenberger J, Hausser H et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002; 30:472–477.PubMedCrossRefGoogle Scholar
  32. 32.
    Kitsukawa T, Shimono A, Kawakami A et al. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995; 121:4309–4318.PubMedGoogle Scholar
  33. 33.
    Vu TH, Shipley JM, Bergers G et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93:411–422.PubMedCrossRefGoogle Scholar
  34. 34.
    Inada M, Wang Y, Byrne MH et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 2004; 101:17192–17197.PubMedCrossRefGoogle Scholar
  35. 35.
    Stickens D, Behonick DJ, Ortega N et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004; 131:5883–5895.PubMedCrossRefGoogle Scholar
  36. 36.
    Ruhrberg C, Gerhardt H, Golding M et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16:2684–2698.PubMedCrossRefGoogle Scholar
  37. 37.
    Midy V, Plouët J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994; 199:380–386.PubMedCrossRefGoogle Scholar
  38. 38.
    Hiltunen MO, Ruuskanen M, Huuskonen J et al. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J 2003; 17:1147–1149.PubMedGoogle Scholar
  39. 39.
    Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor VEGFR1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271:17629–17634.PubMedCrossRefGoogle Scholar
  40. 40.
    Roach HI, Baker JE, Clarke NM. Initiation of the bony epiphysis in long bones: Chronology of interactions between the vascular system and the chondrocytes. J Bone Miner Res 1998; 13:950–961.PubMedCrossRefGoogle Scholar
  41. 41.
    Holmbeck K, Bianco P, Caterina J et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99:81–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhou Z, Apte SS, Soininen R et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97:4052–4057.PubMedCrossRefGoogle Scholar
  43. 43.
    Sounni NE, Roghi C, Chabottaux V et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279:13564–13574.PubMedCrossRefGoogle Scholar
  44. 44.
    Pfander D, Cramer T, Schipani E et al. HIF-1alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. J Cell Sci 2003; 116:1819–1826.PubMedCrossRefGoogle Scholar
  45. 45.
    Pfander D, Kobayashi T, Knight MC et al. Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 2004; 131:2497–2508.PubMedCrossRefGoogle Scholar
  46. 46.
    Stalmans I, Lambrechts D, De Smet F et al. VEGF: A modifier of the del 22q11 (DiGeorge) syndrome? Nat Med 2003; 9:173–182.PubMedCrossRefGoogle Scholar
  47. 47.
    Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34:383–394.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  1. 1.Laboratory for Experimental Medicine and EndocrinologyK. U. LeuvenLeuvenBelgium

Personalised recommendations